A new antibody shot could help infants who contract respiratory ... significant lasting difference in what RSV, how it impacts our community." The treatment is also recommended for older adults ...

The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

Protection against RSV among infants and birthing parents differed by race and ethnicity, indicating the need to ensure equitable access to RSV products.

Ziresovir is the first antiviral to demonstrate significant clinical efficacy and long-term respiratory benefits in ...

RSV is a major respiratory pathogen, particularly among young children, causing severe lower ... ribavirin—an antiviral previously used for RSV treatment—showed minimal efficacy.

Young children with chronic conditions are more likely to be hospitalized for respiratory syncytial virus (RSV) than healthy children, according to a new study.

A  scientific forum held in HCM City on April 27 announced a pioneering preventive method to help prevent lower respiratory ...

The CPS-Ped may be an efficient outcome metric for monitoring disease severity and clinical improvement over time among infants with RSV-related critical illness.

The Lancet Child & Adolescent Health, a leading international journal in pediatric and adolescent medicine, has published the Phase III clinical trial results of ziresovir, a novel RSV-targeted ...

Roughly 8000 Brits died from respiratory syncytial virus infections last year, with tens of thousands likely clogging up ...